European equities traded in the US as American depositary receipts were tracking higher late Monday morning, rising 0.24% to 1,407.61 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies (DBVT) and accommodations booking site trivago (TRVG), which climbed 10% and 5.1%, respectively. They were followed by biotech firm Evaxion Biotech (EVAX) and internet browser company Opera (OPRA), which rose 4.7% and 3.8%, respectively.
The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and medical device maker EDAP TMS (EDAP), which dropped 7.7% and 4.7%, respectively. They were followed by telecommunications operator Telefonica (TEF) and pharmaceutical company Novo Nordisk (NVO), which were down 3.1% and 1.7%, respectively.
From the UK and Ireland, the gainers were led by biotech firm Autolus Therapeutics (AUTL) and cruise line operator Carnival (CUK), which advanced 9.1% and 8.5%, respectively. They were followed by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and pharmaceutical company Silence Therapeutics (SLN), which were up 5.3% and 4.9%, respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and utilities company National Grid (NGG), which fell 12% and 4.2%, respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company NuCana (NCNA), which lost 2.3% and 1.7%, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.